Yves-Marie Pers1, Marie Godfrin-Valnet2, Joseph Lambert2, Clémentine Fortunet2, Elodie Constant2, Thibault Mura2, Béatrice Pallot-Prades2, Christian Jorgensen2, Jean-Francis Maillefert2, Hubert Marotte2, Daniel Wendling2, Philippe Gaudin2. 1. From the Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital; INSERM CIC 1001, Arnaud de Villeneuve University Hospital, Montpellier; Rheumatology, Besançon University Teaching Hospital, Besançon; Rheumatology Unit, Grenoble University Hospital, Grenoble; Rheumatology, Dijon University Hospital, Dijon; Rheumatology Unit, Saint-Étienne University Hospital, Saint-Étienne, France.Y-M. Pers, MD; C. Jorgensen, MD, PhD, Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital; M. Godfrin-Valnet, MD; D. Wendling, MD, PhD, Rheumatology, Besançon University Teaching Hospital; J. Lambert, MD; P. Gaudin, MD, PhD, Rheumatology Unit, Grenoble University Hospital; C. Fortunet, MD; J-F. Maillefert, MD, PhD, Rheumatology, Dijon University Hospital; E. Constant, MD; B. Pallot-Prades, MD; H. Marotte, MD, PhD, Rheumatology Unit, Saint-Etienne University Hospital; T. Mura, MD, PhD, INSERM CIC 1001, Arnaud de Villeneuve University Hospital. ympers2000@yahoo.fr. 2. From the Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital; INSERM CIC 1001, Arnaud de Villeneuve University Hospital, Montpellier; Rheumatology, Besançon University Teaching Hospital, Besançon; Rheumatology Unit, Grenoble University Hospital, Grenoble; Rheumatology, Dijon University Hospital, Dijon; Rheumatology Unit, Saint-Étienne University Hospital, Saint-Étienne, France.Y-M. Pers, MD; C. Jorgensen, MD, PhD, Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital; M. Godfrin-Valnet, MD; D. Wendling, MD, PhD, Rheumatology, Besançon University Teaching Hospital; J. Lambert, MD; P. Gaudin, MD, PhD, Rheumatology Unit, Grenoble University Hospital; C. Fortunet, MD; J-F. Maillefert, MD, PhD, Rheumatology, Dijon University Hospital; E. Constant, MD; B. Pallot-Prades, MD; H. Marotte, MD, PhD, Rheumatology Unit, Saint-Etienne University Hospital; T. Mura, MD, PhD, INSERM CIC 1001, Arnaud de Villeneuve University Hospital.
Abstract
OBJECTIVE: To assess the relationship between the body mass index (BMI) and the efficacy of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA). METHODS: We conducted a retrospective study in 222 patients with RA followed by 5 centers. The European League Against Rheumatism response was evaluated at 6 months. Univariate and multivariate logistic regressions were performed. RESULTS: No significant association between the BMI and the response to TCZ at 6 months was found after adjustment for potential confounding factors (adjusted OR 0.45, 95% CI 0.16-1.24, p = 0.13 and OR 1.19, 95% CI 0.31-4.48, p = 0.78 for BMI 25-30 kg/m(2) and BMI > 30 kg/m(2), respectively, compared to BMI < 25 kg/m(2)). CONCLUSION: Response to TCZ in patients with RA is not influenced by the baseline BMI, in contrast to anti-tumor necrosis factor drugs.
OBJECTIVE: To assess the relationship between the body mass index (BMI) and the efficacy of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA). METHODS: We conducted a retrospective study in 222 patients with RA followed by 5 centers. The European League Against Rheumatism response was evaluated at 6 months. Univariate and multivariate logistic regressions were performed. RESULTS: No significant association between the BMI and the response to TCZ at 6 months was found after adjustment for potential confounding factors (adjusted OR 0.45, 95% CI 0.16-1.24, p = 0.13 and OR 1.19, 95% CI 0.31-4.48, p = 0.78 for BMI 25-30 kg/m(2) and BMI > 30 kg/m(2), respectively, compared to BMI < 25 kg/m(2)). CONCLUSION: Response to TCZ in patients with RA is not influenced by the baseline BMI, in contrast to anti-tumornecrosis factor drugs.
Entities:
Keywords:
BODY MASS INDEX; RESPONSE; RHEUMATOID ARTHRITIS; TOCILIZUMAB
Authors: Yi Xuan Lee; Yu Heng Kwan; Ka Keat Lim; Chuen Seng Tan; Nai Lee Lui; Jie Kie Phang; Eng Hui Chew; Truls Ostbye; Julian Thumboo; Warren Fong Journal: Singapore Med J Date: 2019-06 Impact factor: 1.858
Authors: Ara H Dikranian; Miguel A Gonzalez-Gay; Frank Wellborne; José María Álvaro-Gracia; Liza Takiya; Lori Stockert; Jerome Paulissen; Harry Shi; Svitlana Tatulych; Jeffrey R Curtis Journal: RMD Open Date: 2022-05
Authors: Florenzo Iannone; Delphine S Courvoisier; Jacques Eric Gottenberg; Maria Victoria Hernandez; Elisabeth Lie; Helena Canhão; Karel Pavelka; Merete Lund Hetland; Carl Turesson; Xavier Mariette; Denis Choquette; Axel Finckh Journal: Clin Rheumatol Date: 2016-12-14 Impact factor: 2.980
Authors: A Gardette; S Ottaviani; J Sellam; F Berenbaum; F Lioté; A Meyer; J Sibilia; B Fautrel; E Palazzo; P Dieudé Journal: Clin Rheumatol Date: 2016-01-22 Impact factor: 2.980